03 / 12 / 2020
Benefit from the upcoming in vitro shuttle session - scheduled in April - on our validated immune cell-mediated killing assay to assess novel immunotherapeutics in time and cost-effective manner.
02 / 11 / 2020
Due to the great success of the registration to our shuttle session - which will be held by mid-march - we are pleased to announce, to all who would still be interested, the availability of newly added seats that can be run on a selection of syngeneic tumor mouse models, ie. EMT6 breast cancer CT26 colon cancer and MCA205 sarcoma.
01 / 29 / 2020
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?
01 / 07 / 2020
Initiate the new year with our next in vitro shuttle session on our validated M2 macrophage suppression assay, which will take place by early February – thereby providing an opportunity to timely and cost-effectively assess novel immunotherapeutics.
12 / 03 / 2019
We will be attending the ESMO Immuno-Oncology Congress in Geneva, from December 11 to 14, 2019. We will be glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.
10 / 28 / 2019
We are proud to announce that the French Ministry for Higher Education and Research has recognised Explicyte / Immusmol SAS as a "Credit Import Recherche" (CIR) approved research and development service provider.
10 / 24 / 2019
Nous sommes heureux de vous informer que le Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation a remis un avis favorable au dossier de demande d’agrément Crédit Impôt Recherche déposé par Explicyte / Immusmol SAS.